258 related articles for article (PubMed ID: 19457654)
1. Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study.
Koopman M; Venderbosch S; van Tinteren H; Ligtenberg MJ; Nagtegaal I; Van Krieken JH; Punt CJ
Eur J Cancer; 2009 Jul; 45(11):1999-2006. PubMed ID: 19457654
[TBL] [Abstract][Full Text] [Related]
2. Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastrointestinal adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabine.
Uchida K; Danenberg PV; Danenberg KD; Grem JL
BMC Cancer; 2008 Dec; 8():386. PubMed ID: 19105824
[TBL] [Abstract][Full Text] [Related]
3. Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer.
Meropol NJ; Gold PJ; Diasio RB; Andria M; Dhami M; Godfrey T; Kovatich AJ; Lund KA; Mitchell E; Schwarting R
J Clin Oncol; 2006 Sep; 24(25):4069-77. PubMed ID: 16943524
[TBL] [Abstract][Full Text] [Related]
4. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
[TBL] [Abstract][Full Text] [Related]
5. Modified Irinotecan/5FU/Leucovorin therapy in advanced colorectal cancer and predicting therapeutic efficacy by expression of tumor-related enzymes.
Yanagisawa Y; Maruta F; Iinuma N; Ishizone S; Koide N; Nakayama J; Miyagawa S
Scand J Gastroenterol; 2007 Apr; 42(4):477-84. PubMed ID: 17454858
[TBL] [Abstract][Full Text] [Related]
6. Molecular Biomarker Study in a Randomised Phase III Trial of Irinotecan Plus S-1 versus S-1 for Advanced Gastric Cancer (GC0301/TOP-002).
Tsuburaya A; Sugimoto N; Imamura H; Nishikawa K; Imamoto H; Tsujinaka T; Esaki T; Horita Y; Kimura Y; Fujiya T; Takayama O; Oono R; Yabusaki H; Taguri M; Morita S; Yamada Y; Tan P; Ninomiya M; Furukawa H; Sasako M
Clin Oncol (R Coll Radiol); 2016 Aug; 28(8):e45-51. PubMed ID: 27142170
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of orotate phosphoribosyl transferase among 5-fluorouracil metabolic enzymes in resectable colorectal cancers treated by oral 5-fluorouracil-based adjuvant chemotherapy.
Ochiai T; Nishimura K; Noguchi H; Kitajima M; Tsukada A; Watanabe E; Nagaoka I; Futagawa S
Int J Cancer; 2006 Jun; 118(12):3084-8. PubMed ID: 16425285
[TBL] [Abstract][Full Text] [Related]
8. Factors predicting the response to oral fluoropyrimidine drugs: a phase II trial on the individualization of postoperative adjuvant chemotherapy using oral fluorinated pyrimidines in stage III colorectal cancer treated by curative resection (ACT-01 Study).
Mori T; Ohue M; Takii Y; Hashizume T; Kato T; Kotake K; Sato T; Tango T
Oncol Rep; 2013 Feb; 29(2):437-44. PubMed ID: 23232805
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy.
Soong R; Shah N; Salto-Tellez M; Tai BC; Soo RA; Han HC; Ng SS; Tan WL; Zeps N; Joseph D; Diasio RB; Iacopetta B
Ann Oncol; 2008 May; 19(5):915-9. PubMed ID: 18245778
[TBL] [Abstract][Full Text] [Related]
10. Phase II Trial of Target-guided Personalized Chemotherapy in First-line Metastatic Colorectal Cancer.
Cubillo A; Rodriguez-Pascual J; López-Ríos F; Plaza C; García E; Álvarez R; de Vicente E; Quijano Y; Hernando O; Rubio C; Perea S; Sanchez G; Hidalgo M
Am J Clin Oncol; 2016 Jun; 39(3):236-42. PubMed ID: 24517959
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of 5-fluorouracil metabolic enzyme genes in Dukes' stage B and C colorectal cancer patients treated with oral 5-fluorouracil-based adjuvant chemotherapy.
Yamada H; Iinuma H; Watanabe T
Oncol Rep; 2008 Mar; 19(3):729-35. PubMed ID: 18288408
[TBL] [Abstract][Full Text] [Related]
12. Evaluations of biomarkers associated with sensitivity to 5-fluorouracil and taxanes for recurrent/advanced breast cancer patients treated with capecitabine-based first-line chemotherapy.
Zhao HY; Huang H; Hu ZH; Huang Y; Lin SX; Tian Y; Lin TY
Anticancer Drugs; 2012 Jun; 23(5):534-42. PubMed ID: 22481060
[TBL] [Abstract][Full Text] [Related]
13. Clinical role of orotate phosphoribosyl transferase and dihydropyrimidine dehydrogenase in colorectal cancer treated with postoperative fluoropyrimidine.
Tokunaga Y; Sasaki H; Saito T
Surgery; 2007 Mar; 141(3):346-53. PubMed ID: 17349846
[TBL] [Abstract][Full Text] [Related]
14. Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma.
Lee S; Park YH; Kim KH; Cho EY; Ahn YC; Kim K; Shim YM; Ahn JS; Park K; Im YH
Br J Cancer; 2010 Sep; 103(6):845-51. PubMed ID: 20700125
[TBL] [Abstract][Full Text] [Related]
15. [Thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in soft-tissue sarcoma versus capecitabine potential].
Stepanova EV; Bokhian BIu; Petrovichev NN; Lichinitzer MR
Vopr Onkol; 2005; 51(3):314-6. PubMed ID: 16279094
[TBL] [Abstract][Full Text] [Related]
16. Gene expression profile of 5-fluorouracil metabolic enzymes in primary colorectal cancer: potential as predictive parameters for response to fluorouracil-based chemotherapy.
Kinoshita M; Kodera Y; Hibi K; Nakayama G; Inoue T; Ohashi N; Ito Y; Koike M; Fujiwara M; Nakao A
Anticancer Res; 2007; 27(2):851-6. PubMed ID: 17465211
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Value of Excision Repair Cross-Complementing Gene 1, Dihydropyrimidine Dehydrogenase, and Human Equilibrative Nucleotide Transporter 1 Expression and Their Implications for Adjuvant Treatment in Patients With Ampullary Carcinoma.
Kawabata Y; Nishi T; Kidani A; Tajima Y
Pancreas; 2015 Aug; 44(6):937-44. PubMed ID: 25906447
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
Kim SH; Kwon HC; Oh SY; Lee DM; Lee S; Lee JH; Roh MS; Kim DC; Park KJ; Choi HJ; Kim HJ
Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer.
Kwon HC; Roh MS; Oh SY; Kim SH; Kim MC; Kim JS; Kim HJ
Ann Oncol; 2007 Mar; 18(3):504-9. PubMed ID: 17322540
[TBL] [Abstract][Full Text] [Related]
20. Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer.
Ichikawa W; Uetake H; Shirota Y; Yamada H; Takahashi T; Nihei Z; Sugihara K; Sasaki Y; Hirayama R
Br J Cancer; 2003 Oct; 89(8):1486-92. PubMed ID: 14562021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
